Clinical trials: Breast Neoplasms, Triple-Negative
Breast Cancer
S-equol in Women With Triple Negative Breast Cancer
The primary objective of this study is to determine if S-equol, an ER-beta agonist, is effective in decreasing the proliferation rate of triple negative breast cancer.
- Trial name
- NCT02352025
- Testing
- S-equol
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
This phase I trial studies how well chemokine modulation therapy and standard chemotherapy given before surgery work in treating patients with early stage triple negative breast cancer.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04081389
- Testing
- Celecoxib, Cyclophosphamide, Doxorubicin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
Pucotenlimab and Anlotinib in Combination With Chemotherapy
A prospective, multicenter, single-arm clinical study enrolling patients with histologically confirmed invasive carcinoma, clinical stage II-III, known PD-L1 status, and treatment-naïve triple-negative breast cancer.
- Trial name
- NCT07896668
- Testing
- LP
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Zhejiang Cancer Hospital
Solid Tumor, TNBC - Triple-Negative Breast Cancer
PhI to Solid Tumors and PhII to Locally Advanced or mTNBC
PhI Dose Escalation with BOIN design in advanced Solid Tumor with Triple combination therapy to determine MTD and RP2D
- Trial name
- NCT05390710
- Testing
- LAE005 + Afuresertib + Nab-Paclitaxel
- Where
- 5 sites in China
- Volunteers
- 21 people
- Sponsor
- Laekna Limited
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
Study of High-dose Chemotherapy (HDC) Combined With Adoptive Cellular Therapy With DC-CIK Cells in Triple Negative Breast Cancer Patients
To access the effectiveness of High-dose Cyclophosphamide Combined Chemotherapy combined with adoptive cellular therapy with dentritic and cytokine-induced killer cells in triple negative metastatic breast cancer patients
- Trial name
- DC-CIK (NCT01232062)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Peking University Cancer Hospital & Institute
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Triple-Negative Breast Cancer (TNBC)
Survival Outcomes of Residual Disease in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer associated with a poor prognosis. Although neoadjuvant therapy improves outcomes in patients who achieve a pathological complete response, the…
- Trial name
- ReS-TNBC (NCT07714382)
- Testing
- Chemo-radiotherapy alone, Not applicable- observational study
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
HER2-positive Breast Cancer, HER2 Low
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer
This is an open-label, single-arm, multi-site phase I/Ib trial with SYD985, an antibody-drug conjugate (ADC) targeting HER2 on the cell membrane, combined with paclitaxel.
- Conditions
- HER2-positive Breast Cancer, HER2 Low, SYD-985, SYD985
- Trial name
- NCT04602117
- Testing
- Vic-trastuzumab duocarmazine (SYD985) + paclitaxel
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- QuantumLeap Healthcare Collaborative
Advanced Triple-Negative Breast Cancer
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
This is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast…
- Trial name
- NCT06685796
- Testing
- BEBT-209 capsules, Carboplatin injection, Gemcitabine hydrochloride for injection
- Where
- 2 sites in China
- Volunteers
- 65 people
- Sponsor
- BeBetter Med Inc
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer and HR+/HER2- Metastatic Breast Cancer
This phase II trial studies the side effects and best dose of ivermectin in combination with balstilimab or pembrolizumab and to see how well they they work in shrinking tumors in patients with triple negative breast cancer and…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, HR+ / HER2- Advanced Breast Cancer
- Trial name
- NCT05318469
- Testing
- Ivermectin, Balstilmab, Pembrolizumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Yuan Yuan
Metastatic Breast Cancer
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
The researchers are doing this study to find out if the study drug, enzalutamide, alone or combined with the study drug, mifepristone, is effective in treating advanced or metastatic androgen receptor-positive (AR+) triple…
- Trial name
- NCT06099769
- Testing
- Enzalutamide, Mifepristone, TPC
- Where
- 12 sites in United States
- Volunteers
- 201 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Triple Negative Breast Cancer
QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with metastatic or unresectable TNBC who have progressed on or after anthracycline-based chemotherapy or who have…
- Trial name
- NCT03175666
- Testing
- avelumab, bevacizumab, capecitabine
- Sponsor
- ImmunityBio, Inc.
Breast Cancer Female NOS, General Anxiety Disorder
Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC
This study aims to evaluate whether psychological status affects the response to neoadjuvant immunotherapy in triple-negative breast cancer (TNBC) and how it relates to immune changes during treatment.
- Conditions
- Breast Cancer Female NOS, General Anxiety Disorder, Depressive Disorder
- Trial name
- SCHBCC-N0105 (NCT07290153)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Fudan University
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
ON-treatment Single-cell Analysis for the Identification of Early Tumor Response Biomarkers on Prospective Collected Serial Tumor Biopsies in Triple Negative Breast Cancer Patient During Standard Neoadjuvant Chemo-immunotherapy
This study explores early breast cancer, focusing on triple-negative and high-risk luminal subtypes. It combines single-cell RNA sequencing and spatial imaging of tumor samples collected at different time points during treatment.
- Trial name
- ONSET (NCT07597642)
- Testing
- on treatment biopsy (after C1)
- Where
- Italy
- Volunteers
- 55 people
- Sponsor
- IRCCS San Raffaele
Breast Neoplasms
EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients
The purpose of this study is to assess the efficacy, safety and tolerability of a therapy with EndoTAG-1 + paclitaxel in combination and EndoTAG-1 alone as a rescue therapy for patients with relapsed or metastatic triple receptor…
- Trial name
- NCT00448305
- Testing
- EndoTAG-1 + paclitaxel, EndoTAG-1, Paclitaxel
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 143 people
- Sponsor
- MediGene
Metastatic Breast Cancer
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
The hypothesis of this clinical research study is to discover if the study drug apatinib can shrink or slow the growth of pretreated metastatic triple-negative breast cancer.
- Trial name
- NCT01176669
- Testing
- Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Triple Negative Breast Cancer, Hepatocellular Carcinoma
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable…
- Trial name
- NCT03318562
- Testing
- eFT508
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Effector Therapeutics
Breast Cancer
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in women with triple negative breast cancer whose tumors are positive for a defined pattern of gene expression
- Trial name
- NCT01617668
- Testing
- LCL161, paclitaxel
- Where
- 50 sites in United States, Australia and 10 more
- Volunteers
- 209 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Breast Carcinoma
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
Background: Breast cancer is the most common cancer in US women. There are different types of breast cancers; some are aggressive and difficult to treat.
- Conditions
- Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
- Trial name
- NCT07067138
- Testing
- Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT), TruSight(R) Oncology 500, TruSeq Matched Tumor Normal Whole Exome Sequencing Assay
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.